Nyhetsarkiv for Forskningsgruppe for hjernekreft immunologi og terapi

Glioblastoma (GBM) is malignant brain tumor, where the best available treatment extends survival by approximately 15 months. The tumor has a diffusely infiltrative growth pattern and a microenvironment that makes it difficult to achieve a long-lasting treatment response. Understanding the mechanisms that lead to GBM treatment resistance is imperative for development of novel therapies.